|
楼主 |
发表于 2008-12-10 09:53:51
|
显示全部楼层
68-5-第五节 血管炎的诊断与治疗
系统性血管炎的临床表现复杂多样且无特异性,故给临床诊断带来一定的困难。系统性血管炎需根据临床表现、实验室检查、病理活检资料以及影像学资料包括 X一线胸片、血管造影、CT, MRI等综合判断,以确定血管炎的类型及病变范围。如出现无法解释的下列情况时,应考虑血管炎的可能:①多系统损害。②进行性肾小球肾炎或血肌ffF和尿素氮进行性升高。③肺部多变阴影或固定的阴影/空洞。④多发性单神经根炎或多神经根炎。⑤不明原因发热。⑥缺血性或淤血性症状。⑦紫瘫性皮疹或网状青斑。⑧结节性坏死性皮疹。⑨无脉或血压升高。⑩不明原因的耳鼻喉或眼部病变。)ANCA,AECA阳性。此外,在作出血管炎诊断时应除外感染、肿瘤以及弥漫性结缔组织病,如系统性红斑狼疮、类风湿关节炎、干燥综合征等。 # @6 F: z- I- w
: J1 \# e4 q3 I; \ y( J: x
血管炎的治疗原则是早期诊断、早期治疗,以防止不可逆的损害。患者一旦确诊为血管炎,就应积极治疗,即使尚未明确分型,以免因分型而延误病情,贻误治疗时机。血管炎的常用治疗药物为糖皮质激素和免疫抑制剂,后者以环磷酞胺最为常用。部分血管炎,如川崎病使用IVIg(静脉用丙种球蛋白)具有良好效果。其他还可试用血浆置换。近年来,不断地有新的生物制剂用于临床。抗感染治疗在韦格纳肉芽肿的治疗中具有作用。各种血管炎的具体治疗方法见各论。 Y2 h0 s+ _9 ]2 w/ v/ f, u* ~
( s) M; K# z$ Z4 k. E& N
为了评估血管炎的病情活动情况,各国学者制定了不少评分标准,较常用的有系统性坏死性血管炎的伯明翰评分 (Birmingham vas-culitis activity score, BVAS) ,Olsen等制定的血管炎活动指数(Vasculitis activity index, VAI)和Kallenberg等制定的韦格纳肉芽肿的疾病活动评分标准(Criteria for disease activity in We-gener' s granulomatosis) o这些评分标准用于评估病情和预后,指导治疗。血管炎在合并感染以及并发其他疾病时,临床表现可以类似于病情活动,为区别于病情本身的活动,可采用BVAS进行评估,也具有指导意义。以下给出BVAS评分系统。
. H$ H. b3 [0 ^7 b
. L8 V& A# x l r$ H5 _ 伯明翰系统性血管炎活动评分(Birming-ham vasculitis activity score, BVAS):
+ u- Y0 T8 K9 B k' H* m
' p5 i+ n6 J) T! H/ V5 T+ n 参考文献:
+ K3 b0 a- p( l6 o
/ g' T, W8 P6 M( N/ x: r% k& y Audrian M P, Baranger T A R, Moguilevski N, et al. Antinative and recombinant myeloperoxidase monoclonals and humanantibodies. Clin Exp Immunol 1997. 107:127一134
5 t: E5 E0 Y. ^1 h3 n) _+ c' M
# G( t& x* M# h6 `. c- [ Brasile L, Kremer J M, Clarke J L, et al. Identification ofan autoantibody to vascular endothelial cell-specific antigens in pa-tients with systemic vasculitis. Am J Med,1989. 87:74一80 1 V1 E9 q, L) @
( n! B( D& ^: e
Chan T M, Frampot G, Jayne D R W, et al. Clinical signif-icance of anti-endothelial cell antibodies cell antibodies in systemicvasculitis: a longitudinal study comparing anti-endothelial cell an-tibodies and anti-neutrophil cytoplasm antibodies. Am J KidneyDis,1993. 22:387一392 . A$ u& ]# d' V$ w
- O5 j5 d' P7 p0 ~ Churg J, Strauss L. Allergic granulomatosis, allergic angi-itis, and periarteritis nodosa. Am J Patho1,1951.27: 277一301 9 V7 p2 A0 J& }+ g' f: n
f# j V9 c1 d6 j0 ~! K$ ] Erihhorn J, Sima D, Thiele B, et al. Anti-endothelial cellantibodies in Takayasu arteritis. Circulation, 1996. 94: 2396一2401
6 B/ q+ Y. E/ L! X( A: }! W4 V# k0 P8 n, P2 L9 s
Ewert B H, Jennette J C, Falk R J, et al. Antibodies a-gainst myeloperoxidase stimulate primed neutrophil to damage hu-man endothelial cell in vitro. Kidney Int,1992. 41:375一383
% @, R D( Y" J0 f5 i$ ]* b1 f9 H
" J! y: |3 m2 Y Falk R J, Terrell R S, Charles L A, et al. Anti-neutrophilcytoplasmic autoantibodies induced neutronphils to degranulateand produce oxygen radical in vitro. Proc Natl Acid Sci USA,1990.87:4115一4119
* W' I2 ~5 z+ X \ Frank M M, Basta M, Fries L F. The effects of intravenousimmune globulin on complement-dependent immune damages ofcells and tissues. Clin Immunol Immunopathol,1992.62:S82一86
* `$ g6 L0 H* ~6 D9 [( W2 ^6 k- q
Fujeda M, Oshi N, Kurashige T. Antibodies to aendothelialcells in Kawasaki disease lyse endothelial cells without cytokinepretreatment. Clin Exp Immuno1,1997. 107: 120一126
, g }+ j$ S( t5 d6 D
/ V) g& X4 I4 J) @& F* m" f Gdbel U, Erichhorn J, Kettriz R, et al. Disease activity andautoantibodies to endothelial cells in patients with Wegener' sgranulomatosis. Am J Kidney Dis,1996. 28: 186一194 0 c5 m# L5 a% b) K
6 }0 u6 p1 \% O# r" ^
Haynes B F. Vasculitis: Pathogenic mechanisms of vesseldamage. In: Gallin JI, Goldstein IM, Snyderman R, eds. In-flammation: basic principles and clinical correlates. New York:Raven Press, 1992.921一941
9 ^: j" \% F; E, M, H" v% Y1 t% l2 H% C4 y3 E8 K( D4 S1 O6 {
Hoffman D S. Vasculitis syndromes: editorial overview.Curr Opin Rheumato1,1994. 6:1一2
$ q" f1 [/ Z- E+ E/ p3 o2 Z4 K1 s' J: U0 f
Hunder G G, Arend W P, Bloch DA, et al. The AmericanCollege of Rheumatology 1990 criteria for the classification of vas-culitis. Introduction. Arthritis Rheum, 1990. 33:1065一1067 + q: f3 D& Y3 B8 ]: Y5 y
3 F H4 h7 N' O) L Jennette J C, Falk R J, Andrassy K, et al. Nomenclature ofsystemic vasculitides. Proposal of an international consensus con-ference. Arthritis Rheum, 1994. 37:187一192
1 Y7 x" k8 H; E4 u7 o: G
1 A) L0 L6 P1 I- E( [9 P7 k Jennette J C, Falk R J. Small vessel vasculitis. N Engl JMed, 1997.337:1512一1513
* u! E1 u$ Y0 h; H2 ^$ ?! M, [' S2 N/ Y
Kammer G M, Soter N A, Schur P H. Circulating immu-nune complexes in patients with necrotizing vasculitis. Clin Immunol Immunopatho1,1980. 15:658一672
+ H" A3 B9 G7 g- W
' w( Z5 M# F% t& J Kaneko K, Savage C O S, Pottinger B E, et al. Antien-dothelial cell antibodies can be cytotoxic to endothelial cells with-out cytokine pre-stimulation and correlate with ELISA antidodymeasurement in Kawasaki disease. Clin Exp Immuno1,1994. 98:264一269 7 c/ H+ i- _7 v& O* d9 g
/ A p; u- ^6 J4 S5 k
Lie J T. Nomenclature and classification of vasculitis: Plus cachange, plus c' est la meme chose. Arthritis Rheum, 1994. 37:181一186
7 x8 L' z/ i/ y K$ o; g6 U% h" O3 X3 m/ ~ B
Lockwood C M, Thiru S, Isaacs J D, et al. Long-term ree-mission of intractable systemic vasculitis with monoclonal antibodytherapy. Lancet, 1993. 341:1620一1622
x$ Z& @) ?: q& H( s$ `0 K0 ~* d& k* q% l& v; `# v
Luqmani R A, Bacon P A, moots R J, et al. Birminghamvasculitis activity score (BVAS) in systemic necrotizing vasculitis.Q J Med,1994.87:671一678 " h5 s! E+ H# L- B [8 c2 l
6 G% h* P2 c/ k* s! g4 {" D
McCluskey R T, Fienberg R. Vasculitis in primary vasculi-tides, granulomatoses, and connective tissue disease. HumPathol,1983. 14:305一315
. o/ t1 ]1 {% `( E& ]
6 @, u: i4 m2 M' c% L5 C Papa N D, Guidall L, Sironi M, et al. Anti-endothelial cellIgG antibodies from patients with Wegener's Granulomatosis bindto human endothelial cells in vitro and induce adhesion moleculeexpression and cytokine secretion. Arthritis Rheum, 1996. 39:758一766 . W7 k0 x) c4 P7 [3 I7 g
( G4 U. q7 X1 b
Prapromik S, Blank Miri, Meroni P, et al. Classification ofanti-endothelial cell antibodies into antibodies against microvascu-lar and macrovascular endothelial cell. Arthritis Rheum, 200144:1484一1494
$ ^6 M, V& @& k: @
( E1 |) y& s8 `' s Savage C O S, Pottinger B E, Gaskin G, et al. Vasculardamage in Wegener's granulomatosis and microscopic polyarteri-tis: Presence of Antiendothelial cell antibodies and their relation toanti-neutrophil cytoplasm antibodies. Clin Exp Immunol, 1991.85:14一19 $ z; e/ I' b o( s. y
; D& H, W, f9 q; ]& @) E6 s+ X Savage C O S, Pottinger B E, Gaskin G, et al. Autoanti-bodies developing to myeloperoxidese and proteinase 3 in systemicvasculitis stimulate neutronphil cytotoxicity toward cultured en-dothelial cells. Am J Pathol,1992. 41:375一383 9 O" \, H7 S( h) w4 b
+ d# i* }* Y7 N$ }& x Schifferli J A, Yin C N, Peters D K. The role of comple-ment and its receptor in the elimination of immune complexes. NEngl J Med,1986. 315:488一495
7 s/ G( P4 }/ l, ` {3 z* B, G+ @, c0 q+ W
Wegener F, iiber generalisiete, septische gefasserkrankungen.Verb Dtsch Ges Pathol,1936. 29:202一210 & ], S+ M0 m# R6 K$ a
Westphal J R, Boerbooms A M T H, Schalkwijk C J M, etal. Anti-endothelial cell antibodies in sera of patients with autoim-mune diseases: comparison between ELISA and FACS analysis.Clin Exp Immuno1,1994. 96:444一449
! k) \4 ?+ T8 e4 b9 g+ C0 j ^& i3 @* N0 U. P( i
Zeek P M. Periarteritis nodosa: a critical review. Am JPathol,1951.22:777一79。 |
|